Payment overview · 2025
General Payments
$643.08
38 reported records · 10 companies
Healthcare provider profile · identity verified
Ketankumar N Vaidya, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · EDISON, NJ · NPI 1487688586
Verified facts
What the public records show
CMS Open Payments records show Ketankumar N Vaidya, MD received $643.08 in general payments during 2025 across 38 reported records.
Dexcom, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Mounjaro, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $163.67 | 25.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.55 | 23.7% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.95 | 9.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.18 | 9.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.03 | 7.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.69 | 7.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.11 | 7.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.12 | 4.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.43 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.35 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.78 | 36 |
| Education | $19.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $163.67 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $142.90 | 12 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $124.01 | 11 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.95 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.18 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.69 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $45.11 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 365 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 267 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
267 | 49 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
365 | 67 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
293 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
280 | 43 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
240 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1763 | 380 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1228 | 220 |
| Metformin Hcl | Metformin Hcl | 932 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 882 | 198 |
| Losartan Potassium | Losartan Potassium | 799 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 747 | 189 |
| Diclofenac Sodium | Diclofenac Sodium | 605 | 150 |
| Gabapentin | Gabapentin | 543 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 525 | 123 |
| Eliquis | Apixaban | 434 | 63 |
| Lisinopril | Lisinopril | 422 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 416 | 86 |
| Omeprazole | Omeprazole | 415 | 91 |
| Simvastatin | Simvastatin | 389 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 378 | 79 |
| Furosemide | Furosemide | 375 | 89 |
| Farxiga | Dapagliflozin Propanediol | 365 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 330 | 71 |
| Azithromycin | Azithromycin | 311 | 206 |
| Jardiance | Empagliflozin | 293 | 44 |
| Trulicity | Dulaglutide | 280 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 275 | 61 |
| Linzess | Linaclotide | 267 | 49 |
| Mirtazapine | Mirtazapine | 267 | 47 |
| Famotidine | Famotidine | 265 | 54 |
| Entresto | Sacubitril/Valsartan | 240 | 41 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 237 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 226 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 44 |
| Carvedilol | Carvedilol | 223 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 47 |
| Montelukast Sodium | Montelukast Sodium | 207 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 62 |
| Hydrocortisone | Hydrocortisone | 186 | 71 |
| Meloxicam | Meloxicam | 178 | 59 |
| Atenolol | Atenolol | 177 | 30 |
| Repaglinide | Repaglinide | 171 | 29 |
| Januvia | Sitagliptin Phosphate | 159 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 157 | 31 |
| Glimepiride | Glimepiride | 156 | 30 |
| Methylprednisolone | Methylprednisolone | 153 | 103 |
| Memantine Hcl | Memantine Hcl | 150 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 148 | 50 |
| Donepezil Hcl | Donepezil Hcl | 138 | 18 |
| Alprazolam | Alprazolam | 132 | 31 |
| Metformin Hcl Er | Metformin Hcl | 131 | 28 |
| Xarelto | Rivaroxaban | 129 | 16 |
| Finasteride | Finasteride | 128 | 30 |
| Valsartan | Valsartan | 128 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 113 | 25 |
| Ammonium Lactate | Ammonium Lactate | 107 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 105 | 14 |
| Olanzapine | Olanzapine | 105 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 99 | 31 |
| Latanoprost | Latanoprost | 90 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 66 |
| Prednisone | Prednisone | 89 | 63 |
| Lokelma | Sodium Zirconium Cyclosilicate | 86 | 13 |
| Alendronate Sodium | Alendronate Sodium | 85 | 19 |
| Enalapril Maleate | Enalapril Maleate | 85 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | suppressed |
| Glipizide | Glipizide | 82 | 20 |
| Buspirone Hcl | Buspirone Hcl | 81 | suppressed |
| Levofloxacin | Levofloxacin | 81 | 54 |
| Sucralfate | Sucralfate | 77 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 76 | 14 |
| Irbesartan | Irbesartan | 76 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 76 | 14 |
| Tradjenta | Linagliptin | 76 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 75 | 42 |
| Divalproex Sodium | Divalproex Sodium | 75 | 11 |
| Nifedipine Er | Nifedipine | 75 | 20 |
| Mounjaro | Tirzepatide | 73 | 13 |
| Telmisartan | Telmisartan | 73 | 14 |
| Allopurinol | Allopurinol | 67 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 55 |
| Celecoxib | Celecoxib | 65 | 16 |
| Ozempic | Semaglutide | 64 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 18 |
| Aripiprazole | Aripiprazole | 61 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 61 | 14 |
| Potassium Chloride | Potassium Chloride | 59 | 15 |
| Levetiracetam | Levetiracetam | 57 | 14 |
| Nystatin | Nystatin | 57 | 20 |
| Rybelsus | Semaglutide | 57 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 16 |
| Risperidone | Risperidone | 55 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Lorazepam | Lorazepam | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 31 |
| Ramipril | Ramipril | 53 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 52 | suppressed |
| Torsemide | Torsemide | 50 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Loperamide | Loperamide Hcl | 44 | 15 |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 11 |
| Glipizide Er | Glipizide | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 28 |
| Alcohol Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | 13 |
| Procrit | Epoetin Alfa | 39 | 11 |
| Roflumilast | Roflumilast | 39 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 27 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 35 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 32 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Klayesta | Nystatin | 31 | 17 |
| Lactulose | Lactulose | 31 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 22 |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 29 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Desloratadine | Desloratadine | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Cyclosporine | Cyclosporine | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | 15 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Tirosint | Levothyroxine Sodium | 23 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 23 | 11 |
| Alogliptin | Alogliptin Benzoate | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 20 |
| Topiramate | Topiramate | 20 | suppressed |
| Verquvo | Vericiguat | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Erythromycin | Erythromycin Base | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Felbamate | Felbamate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Acetylcysteine | Acetylcysteine | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | 13 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Perphenazine | Perphenazine | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Mefloquine Hcl | Mefloquine Hcl | 12 | 12 |
| Naproxen | Naproxen | 12 | 12 |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $643.08 · 38 records | Dexcom, Inc. | BREZTRI, CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, LEQVIO, LINZESS, Leqembi, MOUNJARO, OTEZLA, REPATHA, VERQUVO, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error